Up­dat­ed: Verve plans first in-hu­man base edit­ing tri­al in the US af­ter FDA lifts clin­i­cal hold

Verve Ther­a­peu­tics is plan­ning to be­gin an in-hu­man base edit­ing tri­al in the US in pa­tients with het­erozy­gous fa­mil­ial hy­per­c­ho­les­terolemia (HeFH) af­ter the FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER